SCHEMBL7018562

SCHEMBL7018562

CC(OCn1cnc2ccc(I)cc21)[Si](C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
APAF1 O14727 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
BRD4 O60885 4/20 0.32
QPCT Q16769 3/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
EP300 Q09472 1/20 0.31
CREBBP Q92793 1/20 0.31
MAPK1 P28482 2/20 0.31
KCNH2 Q12809 1/20 0.31
QPCTL Q9NXS2 1/20 0.31
LMNA P02545 4/20 0.31
SMN1; SMN2 Q16637 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7018800 0.90 MAPT (0.35) POLBAPAF1MEN1KMT2ATDP1
SCHEMBL7016871 0.85 MAPT (0.41) POLBMTNR1AMTNR1BAPAF1BRD4
SCHEMBL7475809 0.81 TDP1 (0.53) APAF1MEN1KMT2ATDP1CYP11B1
SCHEMBL7017087 0.81 AAK1 (0.40) BRD4QPCT
SCHEMBL2321351 0.80 POLB (0.37) POLBMEN1KMT2ABRD4NPC1
SCHEMBL2541710 0.80 POLB (0.37) POLBMEN1KMT2ABRD4NPC1
SCHEMBL7022413 0.80 FGFR1 (0.46) POLBNPC1RAB9AMAPK1SMN1; SMN2
SCHEMBL7019257 0.77 MAPT (0.55) POLBQPCTCYP11B1CYP11B2QPCTL
SCHEMBL18231503 0.74 NPC1 (0.42) POLBMEN1KMT2ATDP1NPC1
SCHEMBL30762581 0.74 NPC1 (0.42) POLBMEN1KMT2ATDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed